MN-166: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 March 2024

26 March 2024

  • curprev 23:0423:04, 26 March 2024‎ Lazy talk contribs‎ 1,646 bytes +1,646‎ Created page with "{{TreatmentInfo |drug_name=MN-166 (Ibudilast) |FDA_approval=Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions |used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder |clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder |commo..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=MN-166"